Carl Zeiss Meditec Offers Entire Spectrum of Cataract Surgery Solutions.
DUBLIN, Calif. -- An entire suite of cataract surgery solutions, including diagnostics for pre- and post- treatment as well as implantable intraocular lenses (IOLs) and disposables, will be showcased at the American Society of Cataract and Refractive Surgery (ASCRS) meeting in San Francisco by Carl Zeiss Meditec, a leader in complete ophthalmic systems including IOLs and disposables.
"We are excited to offer comprehensive cataract solutions to help surgeons provide the highest quality of care to the growing number of cataract patients worldwide," said Michael Kaschke, President and Chief Executive Officer of Carl Zeiss Meditec. "While our long history and experience in ophthalmology has allowed us to pioneer a vast number of technologies for this market, we also work to ensure that each individual product demonstrates significant value to the practice by implementing practice management benefits and by positively impacting patient outcomes."
Complete Cataract Portfolio
* IOLMaster([R]) - This gold-standard, completely non-invasive biometry system measures axial length, corneal curvature and anterior chamber depth. These important measurements are used to identify the most optimum artificial intraocular lens (IOL) for implantation during cataract surgery.
* OPMI Lumera[R] and OPMI Lumera[R] i - With breakthroughs in illumination technology that increase stability, contrast and brilliance of the red reflex, the gold-standard Lumera microscopes enables clinicians to see the eye in unprecedented detail.
* Visalis 100 - This new phaco-emulsification system enables the surgical removal of the natural, diseased lens from the eye during cataract surgery. Visalis 100 is specifically tailored to the needs of doctors in emerging markets. This product is not approved for sale in the US.
* AT.LISA[R] and AT.LISAtoric - Implanted through incisions of less than 1.5 mm., these are the first intraocular lenses for true micro incision (MICS) refractive cataract surgery. The AT.LISA and AT.LISA toric products are not approved for sale in the US.
* AT.LISA Pre-loaded Solutions - Preloaded solutions for the AT.LISA multifocal and the AT.LISA toric IOLs will be presented in the wetlab station for hands-on practice and demonstration. The lenses are pre-installed into a sterile cartridge, thereby avoiding avoid risk of damage, manipulation and cross-contamination. This new insertion method greatly simplifies the surgical procedure and offers optimal patient comfort.
* CALLISTO eye - A pioneering OR management system customized for ophthalmic surgery, CALLISTO eye simplifies workflow processes during surgery and provides solutions ranging from patient administration via OR planning to video documentation. This product is not approved for sale in the US.
New Offerings for the Refractive Surgeon
The Visante([R]) omni is the first system to combine OCT and Placido disk technologies, providing comprehensive anterior and posterior topography for improved patient selection and care. Linking two of Zeiss' most trusted platforms (the Atlas[TM] corneal topographer with Visante([R]) OCT), the new Visante omni allows the refractive surgeon to identify pre-existing corneal abnormalities, such as keratoconus, in their earliest stages.
"Combining OCT pachymetry with Placido disk technology may provide the most precise information possible about the back surface of the cornea," said Jack Holladay, MD, of Holladay Lasik Institute in Houston, TX. "In addition, the Visante omni Holladay report allows physicians to access patient-specific data sets in a simple, one page printout to maximize workflow and practice efficiencies."
The new 500 kHz VisuMax([R] )Femtosecond System is more than twice the speed of the 200 kHz system, treatment times are reduced from approximately 20 - 25 seconds to just ten seconds per eye. Laser spot density has also been increased by approximately twenty percent, facilitating more consistent flap lifts and smoother stromal beds. This new 500 kHz upgrade works seamlessly with the existing VisuMax platform with no programming modifications required by the surgeon.
"The major advantage of the 500 kilohertz upgrade is that it allows for shorter treatment times with increased laser spot density," said Jon Dishler, MD, of Dishler Laser Institute in Greenwood Village, CO. "Clinically, this produces two significant benefits. First, the higher repetition rate reduces the actual laser emission time, which is the critical phase of the procedure. Thus, the patient is required to remain still for a very short amount of time. Secondly, the higher spot density results in even more precise tissue separation."
Refractive outcomes for the VisuMax([R]) Femtosecond System and the MEL 80[TM] excimer laser will be presented at the "Refractive Surgical Outcomes" symposium on Monday, April 6 from 7 pm to 9:15 pm at the Parc 55 Hotel.
New clinical results will be presented by the Lisa Toric user group during the concurrent "Cataract and Refractive Surgery Outcomes" symposium.
New Independent Market Research
A new market research report compiled by Market Scope Reports will be available to customers and meeting attendees. These research findings demonstrate that while refractive surgery procedures remain relatively flat in today's current environment, a 35 percent increase is expected to take place between 2008 and 2012. Cataract procedures are also anticipated to increase by nearly 13 percent between 2008 and 2012 and 25 percent between 2008 and 2015. These trends are due to an overall decline in the number of practicing ophthalmologists in the coming years combined with an increase in the aging population that will require more medical intervention, particularly in eye care. Please visit booth #1926 to receive a complimentary copy of this report.
Customizable financing programs, designed to meet the unique needs of each practice while addressing burgeoning workflow demands, are also available.
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies.
The Company supplies innovative technologies and application-oriented solutions which enable doctors to improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat ophthalmic diseases. In the field of Neuro/ENT surgery the Company provides innovative visualization solutions. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiotherapy.
The Company's around 2,100 employees generated revenue of about EUR 600 million in fiscal year 2007/08 (ended Sept. 30). The headquarters of Carl Zeiss Meditec are located in Jena, Germany. In addition to other subsidiaries in Germany, the Company is represented by over 50 percent of its employees at sites in the USA, Japan, Spain and France.
Thirty-five percent of Carl Zeiss Meditec's shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world's leading groups engaged in the optical and opto-electronics industry. The five independently run business segments of Carl Zeiss AG operate in the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". Carl Zeiss AG is headquartered in Oberkochen, Germany. During fiscal year 2007/08 (ended Sept. 30) the company generated revenues of about EUR 2.7 billion. Carl Zeiss has around 13,000 employees in more than 30 countries, including more than 8,000 in Germany.
For further information please visit our website at: www.meditec.zeiss.com
|Printer friendly Cite/link Email Feedback|
|Article Type:||Company overview|
|Date:||Apr 6, 2009|
|Previous Article:||Alex A. Hammett Joins Delos Insurance Group as Senior Vice President and Chief Actuary.|
|Next Article:||Rand Paul Speaks to Knob Creek Machine Gun Shootout.|